Page last updated: 2024-12-04

6-hydroxychlorzoxazone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6-hydroxychlorzoxazone: chlorzoxazone metabolite in humans [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2734
CHEMBL ID3182250
CHEBI ID184399
SCHEMBL ID528197
MeSH IDM0117717

Synonyms (33)

Synonym
5-chloro-6-hydroxy-1,3-benzoxazol-2(3h)-one
nsc-24955
1750-45-4
nsc24955
2(3h)-benzoxazolone, 5-chloro-6-hydroxy-
2-benzoxazolinone, 5-chloro-6-hydroxy-
6-hydroxychlorzoxazone, >=98% (hplc)
brn 0911674
nsc 24955
5-chloro-6-hydroxy-2-benzoxazolinone
6-hydroxychlorzoxazone
NCGC00165920-01
FT-0669341
CHEBI:184399
5-chloro-6-hydroxy-3h-1,3-benzoxazol-2-one
AKOS006275736
unii-m5ylt4y73f
m5ylt4y73f ,
5-chloro-6-hydroxybenzoxazone
6-hydroxy chlorzoxazone
5-chloro-6-hydroxybenzo[d]oxazol-2(3h)-one
SCHEMBL528197
AGLXDWOTVQZHIQ-UHFFFAOYSA-N
W-206079
CHEMBL3182250
mfcd00143502
DTXSID50169919
6-hydroxychlorzoxazone, solid
Q61721231
6-hydroxy-chlorzoxazone
C73343
5- chloro- 6- hydroxy- 2(3h)- benzoxazolone
PD019845

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" That is, whether (1) toxic benzene effects are caused by metabolites not derived from phenol (e."( CYP2E1-dependent benzene toxicity: the role of extrahepatic benzene metabolism.
Bernauer, U; Ellrich, R; Gundert-Remy, U; Heinrich-Hirsch, B; Jänig, GR; Vieth, B,
)
0.13

Pharmacokinetics

ExcerptReferenceRelevance
" The concentrations for CZX and OH-CZX over time were simultaneously fitted to a model of first-order elimination of CZX and first-order formation and elimination of OH-CZX using the computer program PCNONLIN to give pharmacokinetic parameters."( Effects of cytochrome P450 2E1 modulators on the pharmacokinetics of chlorzoxazone and 6-hydroxychlorzoxazone in rats.
Chen, L; Yang, CS, 1996
)
0.52
" The pharmacokinetic profile of chlorzoxazone in human following an oral dose of 400 mg was studied."( [Determination of chlorzoxazone and its metabolite 6-hydroxychlorzoxazone in plasma by HPLC and their pharmacokinetics].
Li, L; Zhang, Y, 1998
)
0.55
" The pharmacokinetic parameters including maximum concentration (Cmax), time to reach maximum concentration (Tmax), area under the concentration-time curve (AUC0-8 and AUC0-infinity), elimination half-life (t1/2), elimination rate constant (K(el)), oral clearance (Cl), and volume of distribution (Vd) were determined."( A study on the pharmacokinetics of chlorzoxazone in healthy Thai volunteers.
Komolmit, P; Prompila, N; Wittayalertpanya, S, 2007
)
0.34
"An oral dose of 400 mg CHZ was used to probe for the pharmacokinetic characteristics of this drug in Thai volunteers."( A study on the pharmacokinetics of chlorzoxazone in healthy Thai volunteers.
Komolmit, P; Prompila, N; Wittayalertpanya, S, 2007
)
0.34
" Thus, the time-dependent pharmacokinetic parameters of CZX and OH-CZX were evaluated after the intravenous administration of CZX (20 mg/kg) to control rats, and the 2 h, 24 h and 96 h KPLPS rats along with the time-dependent changes in the protein expression of hepatic Cyp2e1."( Time-dependent effects of Klebsiella pneumoniae endotoxin on the pharmacokinetics of chlorzoxazone and its main metabolite, 6-hydroxychlorzoxazone, in rats: restoration of the parameters in 96 hour in KPLPS rats to control levels.
Choi, YH; Jung, HY; Kang, HE; Kim, SH; Lee, MG, 2009
)
0.56

Dosage Studied

ExcerptRelevanceReference
"We conclude that significant induction of CYP2E1, as indicated by the chlorzoxazone metabolic ratio, occurs in the first month after surgery in liver transplant patients and that drugs that are substrates for CYP2E1 may require dosage alteration during that period."( Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylation.
Branch, RA; Burckart, GJ; Frye, RF; Fung, JJ; Jain, A; Kelly, P; Starzl, TE; Venkataramanan, R, 1998
)
0.3
" The dose-response profile for renal CYP1A1 parallels that in the liver of either species but EROD-activities are 10-20 times lower than in the liver."( Different mechanisms of handling ingested polycyclic aromatic hydrocarbons in mammalian species: organ-specific response patterns of CYP1A1-induction after oral intake of PAH-contaminated soils.
Hack, A; Roos, PH; Tschirbs, S; Welge, P; Wilhelm, M, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzoxazoleCompounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Ethanol metabolism resulting in production of ROS by CYP2E1117
Ethanol metabolism production of ROS by CYP2E1117

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00280.003245.467312,589.2998AID2517
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (61)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (3.28)18.7374
1990's22 (36.07)18.2507
2000's30 (49.18)29.6817
2010's7 (11.48)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.47 (24.57)
Research Supply Index4.26 (2.92)
Research Growth Index5.55 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (12.90%)5.53%
Reviews1 (1.61%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other53 (85.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]